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Dyslipidemia and hyperglycemia in psoriatic inpatients 
Bojan Popchanovski,1 Margareta Balabanova-Stefanova.2 
Abstract 
Background: Psoriasis is a chronic cutaneous T-cell mediated disease, which has been associated with many comorbidities, such as metabolic disorders. 
Specific abnormalities include dyslipidemia, insulin resistance, obesity, and metabolic syndrome, many of which are themselves risk factors for other 
diseases. The goal of this study was to evaluate the presence of dyslipidemia and hyperglycemia in patients with psoriasis. Methods: We compared 48 
inpatients with plaque psoriasis aged 29-79, hospitalized between March 2018 and February 2019, to 48 age- and gender-matched controls. We evaluated 
dyslipidemia and hyperglycemia using enzymatic methods as part of a standard blood test, or medication history indicative of ongoing treatment of 
dyslipidemia and/or hyperglycemia. Hypertension was evaluated by registering blood pressure greater than 140/90 mmHg or ongoing antihypertensive 
treatment. Smoking habits were also noted. Results: There were statistically significant differences between psoriasis patients and controls for elevated 
total cholesterol (p=0,028), elevated LDL (p=0,015), hypertriglyceridemia (p=0,006), and hyperglycemia (p=0,021). The two groups had statistically 
insignificant differences for lowered HDL (p=0,084), hypertension (p=1), and smoking (p=0,836). Conclusion: Hypertriglyceridemia, hyperglycemia, and 
elevated LDL cholesterol were found to be more prevalent in the group containing psoriatic patients compared to the control group. This indicates that 
further investigation of metabolic abnormalities should be conducted in psoriatic patients which could greatly benefit from early treatment of the 
aforementioned underlying conditions. 
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Introduction 
Psoriasis is a chronic immune-mediated skin disorder, with a 
prevalence of 2%.1 TNF-α, IFN-α, IL-23 and Th-17 cells play an 
important role in the pathogenesis of psoriasis.2 Recent evidence 
suggests that metabolic abnormalities are present in the milieu of 
chronic inflammation, as in the case of rheumatological diseases.3 
Chronic inflammation is thought to cause cytokine-induced changes in 
glucose and lipoprotein metabolism,4 alluding to a similar situation 
which happens in the case of insulin resistance caused by cytokines 
secreted by adipose tissue.5 
 
The amount of data on the effect of psoriasis on metabolism is 
increasing, but various results have been reported. For triglyceride 
levels, there are studies that found increased levels6-10 as well as 
statistically insignificant changes.6, 11, 12 There are studies that 
associated psoriasis with higher,12, 13 and others with normal LDL 
cholesterol levels.6, 8, 11, 14-16 As for HDL cholesterol, there are studies 
that associated psoriasis with lower6, 13, 15, 16 HDL levels, and studies that 
did not make that association.8, 11, 12, 14, 17, 18 Correlation was reported 
between psoriasis and diabetes mellitus in some studies9-11, 19, 20 and in 
other studies no such correlation was made.6, 7, 14, 17 Results on 
hypertension and psoriasis were also conflicting, as there are studies 
that established a link9, 10, 19, 20 and studies that did not.7, 15 
 
Quantitative and qualitative changes in lipoprotein metabolism, caused 
by chronic inflammation, may be of potential clinical significance in 
patients with a high risk of cardiovascular comorbidity. This study was 
conducted to examine the correlation between psoriasis and abnormal 
glucose and lipid metabolism. 
 
Methods 
This retrospective study included 48 inpatients (27 males, 21 females) 
with psoriasis vulgaris (plaque and nummularis type) aged 29-79, 
hospitalized in the University Clinic of Dermatology at the Medical 
Faculty in Skopje, between March 2018 and February 2019. Data was 
derived from the clinic's inpatient medical records. Psoriatic inpatients 
that had pustular psoriasis, psoriatic arthritis, erythrodermia, prior 
systemic treatment for psoriasis, concomitant tumors, chronic lung, 
heart, kidney and rheumatological diseases were excluded from the 
study. These 48 inpatients were paired with another 48 inpatients, 
matched for age (±1 year) and gender, hospitalized within the same 
timeframe, and on the same clinic. The exclusion criteria were the same 
for this group. The diagnoses of the control group inpatients were the 
following (Figure 1): Urticaria acuta (23), Reactio anaphylactica (5), 
Reactio allergica post ictus ab insectis (4), Erythema multiforme (3), 
Eczema chronicum (3), Oedema Quincke faciei (2), Erysipelas (2), 
Vasculitis (2), Dermatitis arteficialis (1), LABD (1), Lichen ruber planus 
(1), and Ulcera crurum (1). 
 
The variables of interest were triglyceridemia, low-density lipoprotein 
(LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, glycemia, 
blood pressure, and smoking habits. Lipid parameters and blood 
pressure were evaluated according to cutoff values recommended by 
 
Figure 1. Control group diagnoses. 
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the National Cholesterol Education Program's Adult Treatment Panel III 
(ATP III), or ongoing antilipidemic and/or antihypertensive treatment 
according to the patient's medical history. These cutoff values were: 1.7 
mmol/L for triglycerides, 3.3 mmol/L for LDL cholesterol, 1.0 mmol/L for 
HDL cholesterol, 140/90 mmHg for blood pressure. Glycemia was 
evaluated using the cutoff value of 6.1 mmol/L, recommended by the 
World Health Organization21, or ongoing antidiabetic treatment. Smoking 
habits were evaluated using two categories: patients who are non-
smokers, and patients who are currently smoking or have smoked in 
the past. Glycemia and lipid parameters were measured using 
enzymatic methods. Blood pressure was measured with a standard 
mercury sphygmomanometer. RStudio was used to perform a Student's 
t-test and to calculate the odds ratio with 95% confidence interval. 
 
Figure 2. Age of participants. 
 
 
 
Results 
Among the 48 psoriatic patients, 7 were aged between 29-39, 12 were 
aged between 40-49, 11 were aged between 50-59, 16 were aged 
between 60-69, and 2 were aged between 70-80, as showed in Figure 2. 
Identical distributions were present in the control group. In the 
psoriasis group, 14 patients (29,17%) had hyperglycemia, compared to 
5 (10,42%) in the control group (p=0,021, OR 3.54, 95%CI 1.16-10.81). 
Hypertriglyceridemia was noted in 16 psoriatic patients (33,33%), and 
in 5 patients (10,42%) in the control group (p=0,006, OR 4.30, 95%CI 
1.43-12.96). LDL cholesterol was increased in 16 psoriatic patients 
(33,33%), compared to 6 (12,5%) control patients, (p=0,015, OR 2.14, 
95%CI 0.50-9.12). The differences between the psoriasis group and the 
control group were statistically insignificant for the remaining 
parameters. Ten (20,83%) psoriatic inpatients had lowered HDL 
cholesterol, compared to 4 (8,33%) control patients (p=0,084, OR 2.89, 
95%CI 0.84-9.98). In the psoriasis group, 19 patients (39,58%) reported 
to have smoked or were current smokers, compared to 16 (33,33%) in 
the control group (p=0,836, OR 1.31, 95%CI 0.57-3.02). Finally, 16 
patients in each group were found to have hypertension (p=1, OR 1.00, 
95%CI 0.43-2.34). A summary of the results is given in Table 1 and Figure 3. 
 
Discussion 
Despite the conflicting findings of the current body of research on this 
topic, there is a complex pathophysiological explanation for the 
quantitative and qualitative changes in the case of rheumatological 
diseases, which may also be true for psoriasis. Proinflammatory 
cytokines released during the course of these diseases change many 
aspects of lipid metabolism, such as increased VLDL and triglyceride 
levels via increased hepatic fatty acid synthesis, decreased hepatic 
fatty acid oxidation and increased adipose tissue lipolysis. This 
ultimately contributes to the increase of triglyceride content in LDL and 
HDL particles, which subsequently leads to the formation of small dense 
LDL (sdLDL) particles. These particles are more atherogenic as a result 
of their high susceptibility to oxidation, high affinity for intra-arterial 
proteoglycans, and decreased clearance due to decreased affinity for 
LDL receptors. Additionally, lipoprotein lipase (LPL) activity is reduced, 
which further reduces the clearance of LDL particles.3 
 
Table 1. Associated factors with psoriasis. 
 
 
Parameter Psoriasis Controls p-value OR (95% CI) 
Mean age 52,92 52,73 - - 
Sex 
(male/female) 27/21 27/21 - - 
Smokers 19 16 0,836 1.31(0.57-3.02) 
↑gly 14 5 0,021 3.54 (1.16-10.81) 
↑TAG 16 5 0,006 4.30 (1.43-12.96) 
↓HDL 10 4 0,084 2.89 (0.84-9.98) 
↑LDL 16 6 0,015 2.14 (0.50-9.12) 
↑BP 15 16 1 1.00(0.43-2.34) 
 
Legend: OR - odds ratio, CI - confidence interval, ↑gly - hyperglycemia, ↑TAG - 
elevated triglycerides, ↓HDL - elevated HDL cholesterol, ↑LDL - elevated LDL 
cholesterol, ↑BP – hypertension. 
 
HDL particles are also subject to change in an inflammatory milieu, 
which equates to reverse cholesterol transport being severely impacted 
as a result. Apo A-1 clearance is increased due to decreased synthesis 
and increased breakdown in the kidneys, which both lead to lower 
affinity of Apo A-1 for HDL particles. Serum amyloid A (SAA), an acute 
phase protein generated during inflammation, binds to HDL particles, 
which lowers the affinity of Apo A-1 for its receptor, and increases the 
clearance of HDL particles. Cholesterol ester transfer protein (CETP) and 
lecithin-cholesterol acyltransferase (LCAT) levels are decreased, which 
lead to decreased cholesterol transport from HDL particles and 
decreased cholesterol ester formation, respectively. Certain 
phospholipid and cholesterol membrane transport proteins, such as 
ABCA1, ABCG1, and SR-B1, have reduced activity, which contributes to 
decreased hepatocyte uptake and decreased efflux from macrophages. 
Finally, lipoprotein (a) is generated, which has a high atherogenic 
potential.3 This evidence of qualitative changes in lipoproteins suggests 
that perceived normal lipid levels may not be enough to exclude 
abnormalities in lipid metabolism. 
 
The inflammatory pathogenesis of psoriasis suggests that, skin and 
joint lesions aside, many more less visible metabolic effects may be 
present. Psoriasis causes slight but clinically actionable alterations in 
certain metabolic parameters, which are relevant in terms of 
cardiovascular comorbidity. 
 
This study could be improved by increasing the sample size to increase 
the accuracy of the data and to narrow down the confidence intervals. 
An important drawback represents its retrospective design. The data 
gathered were only the parameters that are measured during routine 
examination in our clinic. Ethnicity is also one of these parameters not 
registered routinely, which may influence the prevalence, age of onset, 
disease course, and further changes to metabolic parameters. 
Additional useful parameters such as Psoriasis Area and Severity Index 
(PASI) and hsCRP, to determine the extensiveness of the psoriatic 
lesions and the cardiovascular risk, respectively, could be measured 
and tested more appropriately in a case-control scenario. 
 
Another aspect not covered in this study is disease progress. Our 
results are only indicative of one point in time, and the history of 
disease progress and treatment for each individual patient is unknown. 
Five of the previously mentioned studies stated that their objective was 
to determine the prevalence specifically of metabolic syndrome in 
psoriatic patients7, 9, 10, 14, 17, 22. Four of them associated psoriasis with 
metabolic syndrome,7, 9, 10, 17 and one found no such link14. One of these 
previously mentioned studies established a dose-response relationship 
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between the severity of psoriasis and the prevalence of metabolic 
syndrome10, while another disproved that22. One meta-analysis, taking 
12 studies into account, also established a dose-response relationship4. 
These diverse findings pertaining to the metabolic syndrome, combined 
with the diverse aforementioned results on individual metabolic 
parameters, indicate that many other factors, such as age of onset, 
duration, disease severity, and treatment, may play a role in terms of 
the order in which metabolic changes appear, and in the way they 
evolve over time. Consequently, we think that the next step in psoriasis 
research could be the effect of the dynamics of the PASI score and BMI 
over time and their ability to predict inapparent but forthcoming 
metabolic changes. 
 
Figure 3. Summary of results. 
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